Ph.D. National Taiwan University
My current research focuses on the development of novel anticancer drugs. Via collaboration with Dr. T. L. Su, a medicinal chemist in IBMS, we have demonstrated that several newly synthesized bifunctional alkylating agents are potent anticancer agents. Several of them were even able to overcome the MDR cancer cells. Our recent interest is to design hybrid molecules with dual functions. We have successfully conjugated phthalazine and bis(hydroxymethyl)pyrrole pharmacophores to form hybrids bearing antiangiogenesis and DNA interstrand crosslinking activities. We have demonstrated these hybrids displaying a broad-spectrum anticancer activity.
I served as PI of Taiwan Biobank (https://www.twbiobank.org.tw). The Taiwan Biobank is a national scientific infrastructure providing the biomedical research community access to biological specimens and information collected from the genereal population in Taiwan. The objective Taiwan Biobank is to recruit 200,000 voluntary participants. Currently, we have recruited 148,291 participants and produced more than 100,000 whole genome genotyping.
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine Hybrids That Inhibit Angiogenesis and Induce DNA Cross-LinksJournal of Medicinal Chemistry, Aug 30, 2021
SAHA Overcomes 5-FU Resistance in IFIT2-Depleted Oral Squamous Cell Carcinoma CellsCancers, Nov 26, 2020